# CT3001

Source: https://onco.cc/drugs/ct3001/  
OnCo record `ct3001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma.

## Summary

CT3001 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Crossignal Therapeutics, Inc., in colorectal cancer, pancreatic ductal adenocarcinoma. Described in the registry record as a a small molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: CT3001
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a a small molecule inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of CT3001: https://clinicaltrials.gov/search?intr=CT3001

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- trials: [A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06598007/)

---
JSON: https://onco.cc/api/v1/entities/ct3001.json